【SynBioCon】 获 悉，近日， 诺泰生物 （688076.SH）与 诺唯赞生物 （688105.SH）战略签约，合作 成立合资公司，共同推进双方在 合成生物学领域 的业务发展。 这是诺泰生物在小分子技术平台，多肽技术平台和寡核苷酸技术平台的基础上，拓展建设的 合成生物学技 术平台 。公司高度重视科技平台的建设和创新，通过学科交叉推行平台战略，实现产业升级，扩大公司在 医药产品的技术和生产优势，巩固和提升在细分领域的领先地位。 此次战略合作的达成，不仅是诺泰生物（688076.SH）与诺唯赞生物（688105.SH）在业务拓展和技术创新 方面的重要一步，也为整个生物科技行业带来了新的发展机遇。期待双方未来在合成生物学领域内的探索 不仅能在生物医药领域产生重大影响力，还可以在 动物保健 与 农业 等更多领域产能较强的影响力。 合资 公司由诺泰生物控股 。 生物合成是生物学研究的前沿领域，以生物酶作为催化剂为核心。与传统化学反应相比， 生物酶催化展现 出诸多显著优势，如绿色无害、安全性高、特异性极强以及原子经济性高等。 （ Source: 《生物革命：创新改变了经济、社会和人们的生活——麦肯锡全球研究院》（ ...

Core Viewpoint - The article highlights the recognition of Muen Biotechnology as a leading innovator in the field of microbial resources and biomanufacturing, having been shortlisted for the WIPO Global Award 2025, which underscores the importance of intellectual property in driving business growth and sustainable development [1][2]. Group 1: Company Achievements - Muen Biotechnology is the only Guangdong company among the six Chinese enterprises that made it to the WIPO Global Award 2025 top 30, showcasing its significant contributions to microbial technology [1][2]. - The company has established the world's largest and most diverse commercial microbial strain library, preserving over 310,000 strains with independent intellectual property rights, including approximately 15,000 high-value strains and over 6,000 new species [3][5]. - Muen Biotechnology has received various accolades, including being named a "Guangdong Provincial Intellectual Property Demonstration Enterprise" and a "Key Agricultural Leading Enterprise" [3]. Group 2: Intellectual Property Strategy - The company has submitted a total of 209 patent applications globally, including 23 international PCT applications, and has received 71 invention patents in China, 2 in Australia, and 2 trademark registrations in the United States [5]. - Muen Biotechnology employs a unique "strain-process-formulation" protection model, ensuring that each high-value microorganism has an average of over five associated patents, creating a robust technical barrier [5]. - The R&D team comprises over 50% of the company's total workforce, with R&D expenditures accounting for approximately 50% of total revenue last year, indicating a strong commitment to innovation [4][5]. Group 3: Market Impact and Future Plans - Muen Biotechnology's agricultural products dominate the new pesticide registration list, with four products listed, and the company serves over 20,000 core growers across 29 provinces in China, covering more than 60 million acres [6]. - The company plans to accelerate PCT international patent applications and expand its technological influence in the fields of biopesticides, microbial proteins, and live microbial drugs [8]. - Muen Biotechnology aims to establish a standard system for microbial resource identification and evaluation in China, promoting global collaboration in research and development [8].

天然生物基因组编码海量的功能基因，这些基因在长期进化选择过程中，占据了广泛的序列空间，并发展 出精巧多样的功能活性，为生物体在复杂环境中的生存和繁衍提供了独特优势。 随着测序获得的生物序列累计达数十亿量级，这些潜在的功能基因也为生物制造和合成生物技术提供了基 因元件的"宝库"。然而，尽管天然基因具备极为丰富的功能和应用潜力，目前只有一小部分热门的功能基因 （如基因编辑工具酶）被高质量注释并构建了序列或结构模型。因此，基于序列、结构或深度学习的基因 挖掘和蛋白质设计方法无法拓展至复杂功能基因，限制了对高价值基因元件的挖掘与开发利用。 【SynBioCon】 获悉，针对上述问题 ， 北京大学定量生物学中心钱珑 团队 于近日推出了 一款面向 合成生物学元件挖掘与生物制造应用的大语言模型 SYMPLEX ， 该模型通过融合领域大语言模型训 练、合成生物专家知识对齐和大规模生物信息分析，实现了从海量文献中自动化挖掘功能基因元件并精准 推荐其工程化应用潜力。 此外， 团队 与 中科院深圳先进技术研究院娄春波研究员 合作，将 SYMPLEX 应用于 mRNA 疫苗生物制 造关键酶—— 加帽酶的挖掘 ，成功获得多种高性能新型 ...

Group 1: Policy Release - The report includes three domestic policies related to the bio-based industry [7][18]. - Key projects in the policies focus on carbon reduction and include initiatives for biodegradable polyester rubber, high-performance bio-based materials, and sustainable aviation fuel [8][19]. Group 2: Industry Dynamics - The report highlights two domestic developments in the bio-based chemicals sector, including a project for lactic acid production and the establishment of a new company for food additives [9][20]. - A total of 13 domestic developments in the bio-manufacturing sector are reported, including strategic collaborations and new project announcements [20][21]. Group 3: Capital Events - Several financing events in the bio-based sector are noted, with companies raising millions in funding for various bio-manufacturing projects [11][22]. - Notable investments include over 100 million yuan for recombinant collagen and nearly 100 million yuan for bioactive ingredients [22]. Group 4: Scientific Research Progress - Significant breakthroughs in scientific research related to bio-based materials and manufacturing are reported, including advancements in bioremediation and the synthesis of high-order carbohydrates [12][23]. - Research highlights include the development of engineered bacteria for pollutant degradation and innovative methods for synthesizing sugars from low-carbon molecules [23]. Group 5: Upcoming Events - The fourth Synthetic Biology and Green Bio-Manufacturing Conference is scheduled for August 20-22, 2025, in Jinan, Shandong, focusing on industry trends and technological innovations [25][26].

Core Viewpoint - The article discusses the evolution of sugar consumption, the rise of high-fructose corn syrup (HFCS), and the emerging trend towards healthier sweeteners like allulose in response to health concerns related to sugar and artificial sweeteners [3][5][7][11][14]. Historical Context - Sugar transitioned from a rare commodity to a staple in modern diets, with its history marked by the cultivation of sugarcane and the establishment of a plantation economy reliant on slave labor [3]. - The "sugar revolution" began in the 16th century as European colonizers introduced sugarcane to the Americas, leading to significant economic impacts and the development of capitalism [3]. Sugar Consumption Trends - In the 17th and 18th centuries, sugar consumption in countries like England increased nearly 20 times over a century, with global consumption reaching approximately 180 million tons annually [5]. - The introduction of HFCS in the 1960s, particularly in the U.S., led to its dominance as a sweetener, with annual consumption around 20 million tons, including 5 million tons in China [5]. Health Concerns - The 21st century has seen rising health concerns regarding HFCS, with studies linking its excessive intake to obesity and diabetes, contributing to a stagnation or decline in demand in Western markets [7]. - Global obesity rates have surged, with over 1 billion adults classified as obese, prompting a shift in consumer preferences towards healthier alternatives [7]. Artificial Sweeteners - The development of artificial sweeteners has progressed through multiple generations, with ongoing debates about their safety and health impacts [9]. - Recent studies have raised alarms about certain artificial sweeteners, such as erythritol and sucralose, potentially increasing the risk of cardiovascular events and other health issues [10]. Shift Towards Healthier Alternatives - Growing health consciousness among consumers has led to the implementation of food health grading systems in various countries, indicating a shift towards healthier dietary choices [11]. - Allulose, a natural sugar discovered 80 years ago, is gaining attention as a promising alternative due to its favorable properties, including low caloric content and minimal impact on blood sugar levels [11][12]. Market Potential for Allulose - Allulose is viewed as a potential mainstream sweetener, with estimates suggesting a market demand of 200,000 tons per year if it achieves a 1% penetration in the global sugar market [14].

【SynBioCon】 获悉，6月3日， 虹摹生物 与 利乐公司 (Tetra Pak)正式达成全球战略合作，标志着"生物智造"与食品工业跨界融合的新阶段正式开 启。 合成生物乳蛋白赛道早已吸引了众多初 创公司、食品巨头和投资机构的目光： 国际布局企业 包括： Perfect Day (美国)、 Remilk (以色列)、 Imagindairy (以色列)、 Change Foods (美国/澳大利亚) 、 New Culture (美国) 、 TurtleTree (新加坡)、Formo / LegenDairy Foods (德国)、Better Dairy (英国)、Triton Algae Innovations (美国)等， 均利用精密发酵生产 酪蛋白，致力于功能、风味、营养价值和规模化开发 。 同时， 食品巨头与配料公司 同样注重这一产品布局： 双方将围绕 未来乳蛋白的创新路径 展开深度协作，共同探索营养升级与可持续发展的新方向，此次合作不仅是 一场强强联合的里程碑事件，更是全球 食品科技在未来营养领域的一次关键布局。 根据协议，虹摹生物与利乐将围绕未来 乳蛋白的创新研发、工艺转化与应用探索展开 ...

Core Viewpoint - The article discusses the intensifying global competition for carbon neutrality and how the bio-based industry can address three major contradictions: reliance on upstream raw materials, certification barriers in the midstream, and limitations in downstream applications [1] Group 1: Event Overview - A closed-door meeting focused on industry breakthroughs was held from May 25-27 during the 2025 Bio-based Conference and Exhibition in Shanghai [4] - The "2025 Bio-based Industry Strategic Seminar" was co-hosted by DT New Materials and the Zhoushan Investment Promotion Center [4] - 25 representatives from industry associations, well-known brands, material companies, and research institutions gathered to discuss three core topics: market reshaping, policy collaboration, and technological breakthroughs [6] Group 2: Key Insights from the Opening Report - The opening report emphasized that bio-based materials are a core pathway for the chemical industry to achieve sustainable development [8] - It highlighted that China's "dual carbon" policy is accelerating implementation, with industry associations promoting collaborative development through policy recommendations, standard setting, and technological rewards [8] Group 3: Brand User Demands - Certification and traceability have become essential prerequisites for collaboration, with international brands requiring non-food bio-based raw material certification [10] - Brands are generally willing to accept a price increase of up to 10%, but significant cost increases could hinder market promotion [11] - Performance must be contextualized, with specific demands for lightweight and decorative bio-based materials in automotive parts and integrated packaging solutions in cosmetics [11] Group 4: Strategies for Bio-based Material Companies - The industrialization of FDCA (2,5-furandicarboxylic acid) faces challenges, with current prices being 40 times that of PTA, making large-scale production crucial for cost reduction [14] - Companies need to identify unique value scenarios beyond merely replacing petroleum-based materials [14] - There is a call for policy collaboration to align with the EU's Packaging and Packaging Waste Regulation (PPWR) and to develop a bio-based materials standard system in China [14] Group 5: AI Empowerment in Bio-manufacturing - Companies shared practices of using AI to reduce R&D costs by 30% through protein modification, enhancing enzyme efficiency, and shortening development cycles [16] - Addressing purity issues is critical for high-end applications, with a need for collaboration across the entire supply chain [16] Group 6: Zhoushan's Strategic Positioning - Zhoushan aims to become a new hub for the bio-based industry by attracting projects related to PLA, PHA, FDCA-PEF, and other materials, providing comprehensive support [17] - The region has already gathered benchmark companies, indicating an initial scale of the industry chain ecosystem [17] Group 7: Consensus on Industry Collaboration - The meeting reached three core conclusions: 1. Non-food raw materials are essential for large-scale commercialization, requiring dual drivers of policy and technological innovation [20] 2. Accelerating the establishment of carbon footprint standards aligned with international norms is necessary to break down green trade barriers [20] 3. Collaboration between brands and material suppliers is needed to shift from performance substitution to value creation [20] - The meeting emphasized that bio-based materials represent a shift in competition rather than a shortcut, necessitating collective efforts across the entire industry chain to overcome the "valley of death" from laboratory to large-scale production [20]

Core Viewpoint - The successful launch of the world's first microbial green manufacturing project for trans-aconitic acid by Qingdao Energy Research Institute and Shandong Lukang Pharmaceutical Co., Ltd. marks a significant breakthrough in the accessibility of this important chemical raw material, which will effectively promote the rapid development of downstream applications such as bio-based materials and biopesticides [1][3]. Group 1: Project Overview - The project was officially launched on May 29, 2024, in Jining, Shandong, and is recognized for overcoming the challenges in microbial green manufacturing technology for trans-aconitic acid [1][3]. - The technology has been evaluated as internationally leading, with strong innovation and advanced indicators, suggesting further expansion of production and application scale [3][4]. Group 2: Technological Innovations - The project utilizes synthetic biology strategies to achieve microbial green manufacturing of trans-aconitic acid for the first time, employing high acid-resistant Aspergillus niger as the chassis cell [3][4]. - Key technological developments include enabling technology platforms, efficient cell factories, fermentation process demonstration, and separation and purification processes, leading to the establishment of the world's first demonstration line for microbial green manufacturing of trans-aconitic acid [3][4]. Group 3: Industry Impact - The collaboration between Qingdao Energy Research Institute and Lukang Pharmaceutical exemplifies interdisciplinary innovation in bio-chemical-materials integration, transforming disruptive technologies into new productive forces [4]. - The project has been recognized as a benchmark for green, low-carbon, and high-quality development, injecting new momentum into the bio-economy sector [5].

团队前期的工作围绕甲醇作为一种可再生的 C1 化合物以及与二氧化碳氢化合成技术的重大突破，通过碳氮协同耦合代谢工程与基因组扰动等多重策 略，有效提升天然甲基营养菌中甲醇向单细胞蛋白的定向转化效率，进而突破工业菌株性能极限，为利用甲醇作为碳源生物制造微生物蛋白大规模工业 化生产提供了关键技术支持；在气态非粮生物制造微生物蛋白方面，通过构建大肠杆菌中的光 - 暗反应能量适配器，实现光驱动 CO 2 同化的全细胞 催化过程；通过电催化 - 生物耦合技术，可将电化学还原 CO 2 生成的甲酸盐与微生物同化模块精准对接，为气态非粮原料的转化技术开辟了负碳生 物制造微生物蛋白的新维度；在固态非粮原料生物合成微生物蛋白技术方面，该团队通过机器学习模型，基于木质纤维素结构特性破译出降解酶系组成 的新算法，进而摆脱复杂性底物结构 - 多样性酶系构效关系的实验先验，精准定制了多种地源性木质纤维素来源的微生物蛋白，达到地源性农业废弃 物资源利用与微生物蛋白生物合成"一草双收"效果。这些创新转化模式不仅提升了农业废弃物资源化利用经济价值，更开辟了农业废弃物规模化生物 合成微生物蛋白的工业化新路径。 以下文章来源于中国科学院天津工业生 ...

Core Viewpoint - The strategic partnership between Suzhou Juweiyuan Biotechnology Co., Ltd. and Kunshan Yaxiang Flavor Co., Ltd. signifies the deep integration of synthetic biology technology and AI with the traditional flavor and fragrance industry, focusing on collaborative innovation in bio-based flavor and fragrance raw materials, green manufacturing pathways, and international market expansion [1][4]. Group 1 - The partnership aims to address the rapidly growing consumer demand for natural, safe, and green flavors and fragrances, positioning synthetic biology as a key opportunity for transforming the industry from petrochemical synthesis to sustainable manufacturing [4]. - Juweiyuan, as a leading synthetic biology enterprise, leverages its proprietary chassis cell library, high-throughput gene editing platform, and AI protein engineering system to overcome critical bottlenecks in the biomanufacturing supply chain [4]. - The collaboration is aligned with China's dual carbon goals, promoting the high-end, green, and international transformation of manufacturing, with a focus on low-carbon alternatives and high-value innovation [4]. Group 2 - The partnership will create a globally leading joint innovation platform for bio-synthetic flavors and fragrances, accelerating the transition of green products from laboratory to market [4]. - The initiative is expected to reshape the supply system and value structure of the flavor and fragrance industry, emphasizing the unique advantages of synthetic biology in raw material substitution, process innovation, and low-carbon manufacturing [4].